Company Overview - Ono Pharmaceutical has a long history dating back to 1717, marking its 309th year in 2023 [3] - The company has developed numerous innovative medicines, including over 10 prostaglandin-related products and the world's first PD-1 antibody, OPDIVO, launched nearly 10 years ago [3] Growth Strategy - Ono is expanding its market focus from traditional Japan and Asia to global markets [4] - In 2024, Ono acquired U.S. biotech Deciphera, aiming to enhance its specialty products and sales channels in the U.S. and European markets [4] Future Outlook - The company is positioned as an attractive investment opportunity with high potential for future growth, driven by its development pipelines [2]